Ongoing SCENESSE® Clinical Trials

Clinuvel is currently conducting one clinical trial of SCENESSE® (afamelanotide 16mg) as a repigmentation therapy in generalised vitiligo. A physician-led studyof SCENESSE® in Hailey-Hailey Disease commenced in early 2014.

In February 2012 Clinuvel filed a marketing authorisation application (MAA) for SCENESSE® with the European Medicines Agency for the orphan disease erythropoietic protoporphria (EPP).

SCENESSE® Blog Posts

In what has become something of a tradition in recent years, yet another country has used the new year to adopt further laws related to...

Read More

Allergan’s lawsuit filed against the FDA presents a relatively novel case in addressing the requirements of drug developers in relation...

Read More

Following on from last week’s conversation, I left off with the issues surrounding the off-label prescriptive habits by physicians and...

Read More

SCENESSE® Webcasts

Taking on Vitiligo, a depigmentation disorder of the skin. In 2010, Clinuvel ventured into an area of dermatology where no other pharmaceut...

Watch now

Taking on Vitiligo, a depigmentation disorder of the skin. In 2010, Clinuvel ventured into an area of dermatology where no other pharmaceut...

Watch now

Taking on Vitiligo, a depigmentation disorder of the skin. In 2010, Clinuvel ventured into an area of dermatology where no other pharmaceut...

Watch now